Barrett's Esophagus
- Home
- Solutions
- By Diseases
- Esophageal Diseases
- Barrett's Esophagus
Barrett's esophagus is the abnormal metaplastic change in the lining of the esophageal mucosa which appears to have a salmon color and also consists of columnar epithelium with goblet cells. Protheragen focuses on advancing scientific knowledge and introducing innovation in therapeutic regarding gastroenterology, especially for Barrett's esophagus and non-common gastrointestinal conditions, and provides all the one-stop services for researchers and scholars.
Barrett's esophagus obliterates normal esophageal squamous cell epithelium and replaces it with a columnar type of metaplasia. It is a well-known precancerous condition and state for esophageal adenocarcinoma, which happens to be a tumor type that has a low survival rate and its incidence has been steadily increasing. About 3 to 5 percent of individuals diagnosed and suffering from Barrett's esophagus will develop esophageal adenocarcinoma in their life expectancy.
Fig.1 Screening guidelines of Barrett's esophagus. (Singh, T., et al., 2019)
The presence of Barrett's esophagus frequently arises from chronic esophagitis, which is further sub-classified as either acidic or non-acidic. Esophageal surveillance using pH has confirmed the correlation that Barrett's esophagus has to prolonged acid exposure. Barrett's esophagus seems to take root as a result of acid insults that cause important transcription factors in progenitor cells to be altered, which further develops metaplasia intestinal. Several pieces of evidence showed that bile salt reflux or nitrogenous compound intake leads to the production of nitric oxide which could cause EB even though these injuries are of the non-acidic variety.
Fig.2 Cellular origins of metaplasia and pathogenesis of Barrett's esophagus. (Maslenkina, K., et al., 2023)| Drug Names | Mechanism of Action | Targets | Research Phase |
| Polyphenon E | A green tea leaf extract that seems to induce cell cycle arrest, trigger apoptosis, and enhance cell-mediated immunity. | / | Phase I |
| Netazepide | Gastrin/CCK2 receptor antagonist. | CCKB | Phase II |
| Celecoxib | Selective inhibition of COX-2. | COX-2 | Phase II |
| Zinc Gluconate | Preventing Barrett's esophagus from becoming malignant and transforming into esophageal cancer. | / | Phase I |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Prioritizing innovation and staying abreast of the latest advancements in gastroenterology research, we deliver cutting-edge solutions for Barrett's esophagus therapeutic. Offering comprehensive diagnostic development, therapeutic development, and disease model development services, our company aims to assist a vast number of researchers, scientists, and companies in the development of effective therapies for Barrett's esophagus and other rare gastrointestinal diseases.
Protheragen is focused on professional animal model development services for Barrett's esophagus and is pleased to offer these services as an effort to further scientific and therapeutic progress within the gastroenterology area.
The surgical model is generated by approximating the small intestine with esophageal mucosa via esophagojejunostomy (EJ) or esophagoduodenostomy (ED).
Genetically engineering models with genetic alterations, such as the IL-1β overexpress model and the p63-deficient model, mimic human Barrett's esophagus.
Diet-induced Model Development
Which can induce BE-like metaplasia in mice such as a zinc-deficient diet combined with DCA administration, a high-fat diet, and exposure to bile acid in 0.2% DCA in drinking water.
The integration of effective project management procedures ensures the delivery of services is prompt, thus assisting clients achieve their project development objectives. With the inclusion of pharmacokinetic studies and drug safety evaluation services, specialized knowledge, and tailor-made strategies, Protheragen strives to move forward with research and innovation in the field of gastroenterology to cater to conditions like Barrett's esophagus that are intricate. If you are interested in our services, please feel free to contact us for more information.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
